CCAGW Urges House of Representatives to Oppose H.R. 6833
Letters to Officials
March 30, 2022
U.S. House of Representatives
Washington, D.C. 20515
Dear Representative,
You will soon be considering H.R. 6833, the Affordable Insulin Now Act. On behalf of the more than one million members and supporters of the Council for Citizens Against Government Waste (CCAGW), I urge you to oppose H.R. 6833 and any other measure to institute price controls in the medical marketplace.
In addition to imposing price controls, H.R. 6833 also increases funding for the Medicare Improvement Fund by $9 billion and adds $1.5 million to the budget for the Centers for Medicare and Medicaid Services to carry out the provisions of the bill.
Historically, price controls like those contained in the Affordable Insulin Now Act increase costs and lead to shortages and rationing. H.R. 6833 will lead to increased premiums for seniors and the 217 million Americans who rely on private health insurance. The government has no business setting prices on any good or service, especially not healthcare. Price controls inherently distort the medical marketplace and leave Americans worse off by significantly decreasing future research and development.
Americans are already suffering under the highest inflation in 40 years, and H.R. 6833 will increase this financial hardship. The cost of medicines should be address without instituting price controls or threatening future innovation. I again urge you to oppose this legislation. All votes on H.R. 6833 may be among those considered in CCAGW’s 2022 Congressional Ratings.
Sincerely,
Tom Schatz
President, CCAGW